1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Arena Sees Phase III Path For Etrasimod After Atopic Dermatitis Miss

Analysts Agreed The S1P Receptor Modulator Should Advance

 
• By Mandy Jackson

Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.

Pathway in the garden outdoor, forward stepping stones or pebbled in the grass lawn.
Arena identified a path forward for etrasimod in atopic dermatitis • Source: Shutterstock

Arena Pharmaceuticals, Inc.’s sphingosine 1-phosphate (S1P) receptor modulator etrasimod did not meet the primary endpoint in the Phase IIb ADVISE clinical trial but the company said its review of data from moderate-to-severe atopic dermatitis patients with uninterrupted courses of treatment show a significant benefit that justifies moving the drug into Phase III testing in the skin disease.

San Diego-based Arena discussed top-line data from ADVISE during a conference call after the stock market closed on 9 November, which had been scheduled to go over the company’s third quarter financial results

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.